Xpert MTB/RIF - why the lack of morbidity and mortality impact in intervention trials?
about
Diagnosis of opportunistic infections: HIV co-infections - tuberculosis.Getting to Zero New Tuberculosis Infections: Insights From the National Institutes of Health/US Centers for Disease Control and Prevention/Bill & Melinda Gates Foundation Workshop on Research Needs for Halting Tuberculosis Transmission.Rapid urine-based screening for tuberculosis in HIV-positive patients admitted to hospital in Africa (STAMP): a pragmatic, multicentre, parallel-group, double-blind, randomised controlled trial
P2860
Xpert MTB/RIF - why the lack of morbidity and mortality impact in intervention trials?
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
2016年论文
@zh
2016年论文
@zh-cn
name
Xpert MTB/RIF - why the lack of morbidity and mortality impact in intervention trials?
@ast
Xpert MTB/RIF - why the lack of morbidity and mortality impact in intervention trials?
@en
type
label
Xpert MTB/RIF - why the lack of morbidity and mortality impact in intervention trials?
@ast
Xpert MTB/RIF - why the lack of morbidity and mortality impact in intervention trials?
@en
prefLabel
Xpert MTB/RIF - why the lack of morbidity and mortality impact in intervention trials?
@ast
Xpert MTB/RIF - why the lack of morbidity and mortality impact in intervention trials?
@en
P2860
P50
P356
P1476
Xpert MTB/RIF - why the lack of morbidity and mortality impact in intervention trials?
@en
P2093
Andrew F Auld
P2860
P304
P356
10.1093/TRSTMH/TRW056
P577
2016-09-16T00:00:00Z